Therapeutic Potential of <sup>47</sup>Sc in Comparison to <sup>177</sup>Lu and <sup>90</sup>Y: Preclinical Investigations

Therapeutic Potential of <sup>47</sup>Sc in Comparison to <sup>177</sup>Lu and <sup>90</sup>Y: Preclinical Investigations

Targeted radionuclide therapy with <sup>177</sup>Lu- and <sup>90</sup>Y-labeled radioconjugates is a clinically-established treatment modality for metastasized cancer. <sup>47</sup>Sc is a therapeutic radionuclide that decays with a half-life of 3.35 days and emit...

Full description

Bibliographic Details
Main Authors: Klaudia Siwowska, Patrycja Guzik, Katharina A. Domnanich, Josep M. Monné Rodríguez, Peter Bernhardt, Bernard Ponsard, Roger Hasler, Francesca Borgna, Roger Schibli, Ulli Köster, Nicholas P. van der Meulen, Cristina Müller
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Pharmaceutics
Subjects:
<sup>47</sup>Sc
<sup>177</sup>Lu
<sup>90</sup>Y
radionuclide therapy
SPECT
folate receptor
DOTA-folate
IGROV-1 tumor xenografts
preclinical therapy
Online Access:https://www.mdpi.com/1999-4923/11/8/424

Similar Items

Similar Items